Jun 19 2026 This Week in Cardiology
Shownotes
Listener feedback, more long-term data on the TAVR/SAVR question, population prevalence of valvular heart disease in the US, and a CMS proposal to expand TAVR coverage are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I Listener Feedback
- ICD Trends and Outcomes: 15-Year Analysis https://doi.org/10.1093/europace/euag110
- MADIT-RIT https://www.nejm.org/doi/full/10.1056/NEJMoa1211107
II More Long Term Data on TAVR vs SAVR
- PARTNER 2 Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.03.169
- 10-Year Outcomes of SAPIEN 3 TAVR or SAVR in Intermediate-Risk Patients https://doi.org/10.1016/j.jacc.2026.03.170
- TAVR at a Decade: Editorial https://doi.org/10.1016/j.jacc.2026.04.042
- EVOLUT Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063
- Updated 5-year Outcomes of TAVR vs SAVR in AS https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092
- NOTION Trial https://doi.org/10.1093/eurheartj/ehae043
- PARTNER 3 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509766
- NOTION 2 Trial https://academic.oup.com/eurheartj/article/45/37/3804/7673297
- TAVR vs SAVR Editorial : https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehag407/8708044
III The PREVUE-VALVE Study
- PREVUE-VALVE Study https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5137
IV CMS has Proposed New Coverage for TAVR
- CMS Proposal Document https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&ncaId=321
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.